143 related articles for article (PubMed ID: 3491878)
1. Allosteric interaction between the site labeled by [3H]imipramine and the serotonin transporter in human platelets.
Meyerson LR; Ieni JR; Wennogle LP
J Neurochem; 1987 Feb; 48(2):560-5. PubMed ID: 3491878
[TBL] [Abstract][Full Text] [Related]
2. Tryptamine, a substrate for the serotonin transporter in human platelets, modifies the dissociation kinetics of [3H]imipramine binding: possible allosteric interaction.
Segonzac A; Raisman R; Tateishi T; Schoemaker H; Hicks PE; Langer SZ
J Neurochem; 1985 Feb; 44(2):349-56. PubMed ID: 3871227
[TBL] [Abstract][Full Text] [Related]
3. A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter.
Graham D; Esnaud H; Habert E; Langer SZ
Biochem Pharmacol; 1989 Nov; 38(21):3819-26. PubMed ID: 2532013
[TBL] [Abstract][Full Text] [Related]
4. Temperature dependence of drug interaction with the platelet 5-hydroxytryptamine transporter: a clue to the imipramine selectivity paradox.
Segonzac A; Schoemaker H; Langer SZ
J Neurochem; 1987 Feb; 48(2):331-9. PubMed ID: 2947974
[TBL] [Abstract][Full Text] [Related]
5. Inhibition and dissociation of [3H]-paroxetine binding to human platelets.
Andersson A; Marcusson J
Neuropsychobiology; 1989; 22(3):135-40. PubMed ID: 2535005
[TBL] [Abstract][Full Text] [Related]
6. Changes in [3H]5-HT uptake and [3H]imipramine binding in platelets after chlorimipramine in healthy volunteers. Comparison with maprotiline and amineptine.
Poirier MF; Galzin AM; Loo H; Pimoule C; Segonzac A; Benkelfat C; Sechter D; Zarifian E; Schoemaker H; Langer SZ
Biol Psychiatry; 1987 Mar; 22(3):287-302. PubMed ID: 3028514
[TBL] [Abstract][Full Text] [Related]
7. 5-Methoxytryptoline, a competitive endocoid acting at [3H]imipramine recognition sites in human platelets.
Segonzac A; Schoemaker H; Tateishi T; Langer SZ
J Neurochem; 1985 Jul; 45(1):249-56. PubMed ID: 2987413
[TBL] [Abstract][Full Text] [Related]
8. [3H]imipramine binding of protein nature in human platelets: inhibition by 5-hydroxytryptamine and 5-hydroxytryptamine uptake inhibitors.
Marcusson J; Tiger G
J Neurochem; 1988 Apr; 50(4):1032-6. PubMed ID: 3279163
[TBL] [Abstract][Full Text] [Related]
9. Relationship between seasonal patterns of platelet serotonin uptake and 3H-imipramine binding in depressed patients and normal controls.
Chicz-DeMet A; Reist C; DeMet EM
Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(1):25-39. PubMed ID: 2008538
[TBL] [Abstract][Full Text] [Related]
10. Effects of N-ethylmaleimide on 5-hydroxytryptamine transport and sodium content in rabbit platelets.
Wölfel R; Halbrügge T; Graefe KH
Br J Pharmacol; 1989 Aug; 97(4):1308-14. PubMed ID: 2790384
[TBL] [Abstract][Full Text] [Related]
11. Influence of age, sex and diurnal variability on imipramine receptor binding and serotonin uptake in platelets of normal subjects.
Halbreich U; Rojansky N; Zander KJ; Barkai A
J Psychiatr Res; 1991; 25(1-2):7-18. PubMed ID: 1851224
[TBL] [Abstract][Full Text] [Related]
12. High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes.
Mellerup ET; Plenge P; Engelstoft M
Eur J Pharmacol; 1983 Dec; 96(3-4):303-9. PubMed ID: 6233162
[TBL] [Abstract][Full Text] [Related]
13. Comparison of [3H]paroxetine and [3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain.
Gurevich EV; Joyce JN
Neuropsychopharmacology; 1996 May; 14(5):309-23. PubMed ID: 8703300
[TBL] [Abstract][Full Text] [Related]
14. Effect of different photoperiod exposure on [3H]imipramine binding and serotonin uptake in the rat brain.
Rovescalli AC; Brunello N; Riva M; Galimberti R; Racagni G
J Neurochem; 1989 Feb; 52(2):507-14. PubMed ID: 2463336
[TBL] [Abstract][Full Text] [Related]
15. Two affinity states for [3H]imipramine binding to the human platelet 5-hydroxytryptamine carrier: an explanation for the allosteric interaction between 5-hydroxytryptamine and imipramine.
O'Riordan C; Phillips OM; Williams DC
J Neurochem; 1990 Apr; 54(4):1275-80. PubMed ID: 2313287
[TBL] [Abstract][Full Text] [Related]
16. Is there a relationship between baseline and treatment-associated changes in [3H]-IMI platelet binding and clinical response in major depression?
Tollefson GD; Heiligenstein JH; Tollefson SL; Birkett MA; Knight DL; Nemeroff CB
Neuropsychopharmacology; 1996 Jan; 14(1):47-53. PubMed ID: 8719029
[TBL] [Abstract][Full Text] [Related]
17. Evidence for various tryptamines and related compounds acting as substrates of the platelet 5-hydroxytryptamine transporter.
Wölfel R; Graefe KH
Naunyn Schmiedebergs Arch Pharmacol; 1992 Feb; 345(2):129-36. PubMed ID: 1570019
[TBL] [Abstract][Full Text] [Related]
18. Methodological issues in the preparation and assay of platelet 3H-imipramine binding.
Severson JA; Schneider LS; Fredrickson ER
Psychiatry Res; 1990 Jul; 33(1):19-29. PubMed ID: 1699244
[TBL] [Abstract][Full Text] [Related]
19. Changes induced by corticosterone and adrenalectomy in synaptosomal and platelet uptake and binding of 5-HT. The relationship to [3H]imipramine binding.
Lee PH; Chan MY
Neuropharmacology; 1985 Nov; 24(11):1043-50. PubMed ID: 4080103
[TBL] [Abstract][Full Text] [Related]
20. Reduced Bmax of [3H]-imipramine binding to platelets of depressed patients free of previous medication with 5HT uptake inhibitors.
Poirier MF; Benkelfat C; Loo H; Sechter D; Zarifian E; Galzin AM; Langer SZ
Psychopharmacology (Berl); 1986; 89(4):456-61. PubMed ID: 3092276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
